共 81 条
Proteomics in colorectal cancer translational research: Biomarker discovery for clinical applications
被引:79
作者:
de Wit, Meike
[1
]
Fijneman, Remond J. A.
[2
]
Verheul, Henk M. W.
[3
]
Meijer, Gerrit A.
[2
]
Jimenez, Connie R.
[1
]
机构:
[1] Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, OncoProte Lab, Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Tumor Profiling Unit, Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, Amsterdam, Netherlands
关键词:
Colorectal cancer;
Biomarkers;
Proteins;
Clinical needs;
Mass spectrometry;
Proteomics;
SPECTROMETRY-BASED PROTEOMICS;
CANDIDATE BIOMARKERS;
CELL-SURFACE;
PROTEIN;
EXPRESSION;
ADENOMA;
IDENTIFICATION;
REVEALS;
GENE;
INSTABILITY;
D O I:
10.1016/j.clinbiochem.2012.10.039
中图分类号:
R446 [实验室诊断];
R-33 [实验医学、医学实验];
学科分类号:
1001 ;
摘要:
Colorectal cancer (CRC) is a major cause of cancer-related death in the western world. Screening to detect the disease in an early stage is the most effective approach to tackle this problem. In addition, better diagnostic tools for assessment of prognosis and prediction of response to drug therapy will allow for personalized therapies and better outcomes. Protein biomarkers that reflect tumor biology have the potential to address a wide range of clinical needs. These include diagnostic (screening) biomarkers for early detection, prognostic biomarkers for estimation of disease outcome, predictive biomarkers for adjuvant treatment stratification, and surveillance biomarkers for disease monitoring and treatment response. An important source for the discovery of potential biomarkers comes from mass spectrometry based proteomics research of the biology of CRC development Here, we review recent colon cancer proteomics studies directed at identification of biomarker proteins. These include studies that use preclinical models (i.e. cell lines or murine tissues) as well as clinical materials (e.g. tissue and stool samples). We separately highlight some studies that focused on identification of cancer stem cell (CSC) related proteins in tumor spheroids, an in vitro model system for investigating CRC treatment response. Recent proteomics studies have generated many new candidate protein biomarkers. However, the lack of follow-up studies that lead to biomarker verification and/or validation remains a limiting factor in the translation of these candidate biomarkers into clinical applications. This is partly due to technological limitations which are bound to diminish with new technologies, including selected reaction monitoring mass spectrometry (SRM-MS). Antibodies are still required, though, both to perform high-throughput validation as well as to develop cost-effective tests for routine use in a clinical setting. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:466 / 479
页数:14
相关论文